Effects of a calcimimetic compound and naturally activating mutations on the human Ca2+ receptor and on Ca2+ receptor/metabotropic glutamate chimeric receptors

被引:68
作者
Hauache, OM
Hu, JX
Ray, K
Xie, RY
Jacobson, KA
Spiegel, AM
机构
[1] NIDDK, Metab Dis Branch, NIH, Bethesda, MD 20892 USA
[2] NIDDK, Bioorgan Chem Lab, NIH, Bethesda, MD 20892 USA
关键词
D O I
10.1210/en.141.11.4156
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Naturally occurring mutations identified in subjects with autosomal dominant hypocalcemia (ADH) and the calcimimetic compound, R-568, have both been reported to increase Ca2+ sensitivity of the Ca2+ receptor (CaR). To gain insight into their mechanism of action, we studied interactions between four different ADR mutations located in the amino-terminal extracellular domain (ECD) and R-568. We found that R-568 increased the sensitivity of three of the ADH mutant receptors, but the Leu125Pro mutant appeared robe maximally left-shifted in that neither R-568 addition nor combining other ADH mutations with Leu125Pro gave increases in sensitivity comparable to those seen with the three other ADH mutations studied. We also made use of truncation and deletion mutants of the CaR and CaR/metabotropic glutamate receptor type 1 (mGluR1) chimeras to study both the site of action of R-568 and the effect of the Leu125Pro activating mutation. R-568 was effective in receptor constructs containing the seven transmembrane domain (7TM) of the CaR, but not in those containing the mGluR1 7TM. R-568, moreover, imparted Ca2+ responsiveness to CaR constructs lacking all or part of the CaR ECD. The Leu125Pro mutation in contrast conferred no or minimal increase in Ca2+ responsiveness to CaR constructs lacking Dart of the CaR ECD but showed a striking increase in basal activity in the context of chimeras containing an mGluR1 7TM. Our results localize the site of action of NPS-568 specifically to the CaR 7TM. Our results with the Leu125Pro mutant, furthermore, suggest that the mGluR1 7TM domain may be more permissive for activation than the 7TM domain of the CaR.
引用
收藏
页码:4156 / 4163
页数:8
相关论文
共 26 条
[1]   Mutations in the Ca2+-sensing receptor gene cause autosomal dominant and sporadic hypoparathyroidism [J].
Baron, J ;
Winer, KK ;
Yanovski, JA ;
Cunningham, AW ;
Laue, L ;
Zimmerman, D ;
Cutler, GB .
HUMAN MOLECULAR GENETICS, 1996, 5 (05) :601-606
[2]   Molecular tinkering of G protein-coupled receptors: an evolutionary success [J].
Bockaert, J ;
Pin, JP .
EMBO JOURNAL, 1999, 18 (07) :1723-1729
[3]   CYANOHYDRIDOBORATE ANION AS A SELECTIVE REDUCING AGENT [J].
BORCH, RF ;
BERNSTEIN, MD ;
DURST, HD .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1971, 93 (12) :2897-+
[4]   The agonist-binding domain of the calcium-sensing receptor is located at the amino-terminal domain [J].
Bräuner-Osborne, H ;
Jensen, AA ;
Sheppard, PO ;
O'Hara, P ;
Krogsgaard-Larsen, P .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (26) :18382-18386
[5]   CLONING AND CHARACTERIZATION OF AN EXTRACELLULAR CA2+-SENSING RECEPTOR FROM BOVINE PARATHYROID [J].
BROWN, EM ;
GAMBA, G ;
RICCARDI, D ;
LOMBARDI, M ;
BUTTERS, R ;
KIFOR, O ;
SUN, A ;
HEDIGER, MA ;
LYTTON, J ;
HEBERT, SC .
NATURE, 1993, 366 (6455) :575-580
[6]   Physiology and pathophysiology of the extracellular calcium-sensing receptor [J].
Brown, EM .
AMERICAN JOURNAL OF MEDICINE, 1999, 106 (02) :238-253
[7]   Treatment of hypercalcemia secondary to parathyroid carcinoma with a novel calcimimetic agent [J].
Collins, MT ;
Skarulis, MC ;
Bilezikian, JP ;
Silverberg, SJ ;
Spiegel, AM ;
Marx, SJ .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1998, 83 (04) :1083-1088
[8]   Sporadic hypoparathyroidism caused by de novo gain-of-function mutations of the Ca2+-sensing receptor [J].
DeLuca, F ;
Ray, K ;
Mancilla, EE ;
Fan, GF ;
Winer, KK ;
Gore, P ;
Spiegel, AM ;
Baron, J .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1997, 82 (08) :2710-2715
[9]   N-linked glycosylation of the human Ca2+ receptor is essential for its expression at the cell surface [J].
Fan, GF ;
Goldsmith, PK ;
Collins, R ;
Dunn, CK ;
Krapcho, KJ ;
Rogers, KV ;
Spiegel, AM .
ENDOCRINOLOGY, 1997, 138 (05) :1916-1922
[10]   Mutagenesis and modeling of the GABAB receptor extracellular domain support a Venus flytrap mechanism for ligand binding [J].
Galvez, T ;
Parmentier, ML ;
Joly, C ;
Malitschek, B ;
Kaupmann, K ;
Kuhn, R ;
Bittiger, H ;
Froestl, W ;
Bettler, B ;
Pin, JP .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (19) :13362-13369